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Methods: A retrospective analysis of 28 patients of acute heart
failure (all due to different spectrum of acute coronary syndrome)
in whom ivabradine was used was done. All of them had an
ejection fraction of <50%, resting heart rate >70 bpm and SBP> 100
mm Hg without inotropes. The patients were receiving standard
guideline directed therapy including beta blockers wherever
indicated. Ivabradine was started in a dose of 2.5 mg BD and
increased upto 7.5 mg BD in accordance with the patient’s clinical
condition. The patient’s clinical parameters were recorded at the
time of initiation of Ivabradine and 24-hours and 7 days after
initiation of therapy.
Results: A total of 28 patients (mean age 60.3 years, 20 males)
constituted the study group. Baseline mean Heart rate (HR) was 96
(70-128) bpm and systolic Blood pressure (SBP) was 110 mm
Hg(100-134mm Hg). Patients in NYHA II, III and IV numbered 19, 9
and 0 respectively when the therapy with ivabradine was started.
HR decreased by 2.7 ± 0.2 bpm after 24 hours (p¼NS) and 14.3 ± 7.2
bpm at day 7 (p ¼ 0.008). The systolic blood pressure decreased by
2.4mmHg after 24 hours (p¼NS) and 4.1mmHg at day 7 (p¼0.091)
. Patients in NYHA class II and III at 24 hours was 20 and 8
respectively. At 7 days, 8 patients were in NYHA I, 17 in NYHA II
and 3 in NYHA III. No worsening of NYHA class was noted in any
patient at 7 days.
Conclusion: Initiating Ivabradine in patients of acute heart failure
during hospital stay is both safe and effective.
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Background: Chronic heart failure is associated with sympathetic
activation characterised by elevated circulating norepinephrine
levels which are linked to cardiovascular morbidity andmortality.
Surgical renal denervation has been shown to improve both renal
and ventricular function, although all these studies have been
conducted on animal models so far. In humans the safety and
efficacy of renal denervation therapy has been studied in treat-
ment of drug resistant hypertension only. Limited data exist
regarding renal denervation therapy in chronic heart failure pa-
tients. All these studies have used specifically desingnedcathers
which are not cost effective especially in developing countries.
Our study is the first randomised study of renal denervation
done in patients of chronic heart failure using standard radio
frequency cardiac ablation cathers.
Aim and objective: To demonstrate the safety and efficacy of renal
denervation therapy in chronic heart failure patients using the
standard cardiac radiofrequency ablation catheter.
Method: Thirty eight patients with chronic heart faiulre with
LVEF< 40 % on optimal heart failure therapy were enrolled and
randomized into two group:
(a) interventional group (n ¼ 18) and; (b) conservative group (n ¼
20). Out of the 18 patients in the interventional arm, 15 underwent
successful bilateral renal denervation. In all these patients stan-
dard radio frequency cardiac ablation cather was used. Patients
were admitted for pre-procedure baseline assessments and in-
patient observation for 2 days following denervation. Follow up
was done at 1st week, one month, three months, six months and
one year.
Results: No significant haemodynamic disturbances were noted
during the acute phase post renal denervation. Over one year of
followup there was a non-significant trend to blood pressure
reduction (Dsystolic 5.2±5.9 mm Hg, p¼0.35; Ddiastolic 1.2± 3
mm Hg, p¼0.70). No hypotensive or syncopal episodes were re-
ported. Renal function remained stable (Dcreatinine 5.7±8.4
mmol/l, p¼0.52 and Durea 1.0±1.0 mmol/l, p¼0.33).
As compared to the conservative group, in the interventional
group there was a significant difference at 12 months of follow
with respect to increase in 6 min walk test(537±103meter to
603±119 vs 499± 98 to 533±99 p 0.001) , increase in LVEF(27.3±11 to
33.1±13 vs 28.1±12 to 30.1± 14 p< 0.001) and reduction in NT -pro
BNP levels(1896 ±79pg/ml to1324±67 pg/ml vs 1903±95 to 1765±89
p<0.001)
Conclusions: This study found no procedural or post procedural
complications following renal denervation in patients with
chronic systolic heart failure at 12 months follow-up. Results
suggested a significant improvement in interventional group as
compared to conservative group in terms of 6 min walk test, LVEF
and NT pro BNP levels.
Hence, to conclude sympathetic renal denervation is not only
safe but also efficient in patients of chronic heart failure and
standard cardiac ablation cathers can be as effective and safe as
specially designed cathers.
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Background: Presence of hsTnT was also a strong independent
predictor of mortality and provided prognostic information in
heart failure patient increamental to that provided by other
powerful predictor of outcome like BNP.
Methods: In this study 100 patient of acute decompensated heart
failure who were admitted in the cardiology indoor of IPGME&R,
SSKM hospital kolkata between February 2012 to September 2013
were enrolled. It is prospective observational study.within 24
hours of admission quantitative serum analysis was done and the
positive were categorized as troponin T positive(>50ng/l) or
troponin T negative(>50ng/l).
Results: The study shows significant number of patients(n¼66)
were positive for hsTnT. Systolic blood pressure is reduced sig-
nificantly(p<0.001) on follow up study in hsTnT positive patients.
FBS(>126mg/dl) is significantly increased on admission in hsTnT
positive patients(131.4+42.9) in compared to hsTnT negative
patients.(mean+SD¼98+33.2) (p¼0.049). LVID(d) is singificantly
increased at admission, discharge and follow up study. The
reduction of EF(%) is statistically significant(p¼0.03CI¼0.75 to 0.94
and odd ratio 0.84) in the three months follow up study. Duration
of stay in hospital is more in hsTnT positive patients than
troponin negative patients as detailed in descriptive study above.
The value become statistically significant in our study(p¼0.001).
Conclusion: The patients with troponin T positivity show higher
mortality (both in hospital and outside) and recurrent hospitali-
zation in comparison with troponin T negative patients. Duration
of stay in hospital is higher for hsTnT positive patients when
compared with troponin negative patients. NYHA class and
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